Sugi Predict

Sugi Predict / Compounds / SCHEMBL15029587

SCHEMBL15029587

SCHEMBL15029587

OCCO[C@H]1CC[C@H](N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 1/20 0.44
▸ SLC6A2 P23975 2/20 0.40
▸ SLC6A4 P31645 2/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ ACKR3 P25106 1/20 0.40
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 3/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ OPRM1 P35372 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CCR5 P51681 1/20 0.35
▸ OPRD1 P41143 1/20 0.35
▸ OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18428842 1.00 YTHDC1 (0.44) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL18365044 0.92 YTHDC1 (0.40) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL18428792 0.92 YTHDC1 (0.40) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL18428790 0.92 YTHDC1 (0.40) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL15009794 0.91 YTHDC1 (0.42) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL15009795 0.91 YTHDC1 (0.42) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL30390461 0.85 YTHDC1 (0.44) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL28984110 0.85 YTHDC1 (0.44) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL23329876 0.84 YTHDC1 (0.43) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3
SCHEMBL5006779 0.84 YTHDC1 (0.43) YTHDC1SLC6A2SLC6A4SLC6A3ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158024-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-05-25 — — US disclosed
US-20230158024-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-05-25 — — US disclosed
US-20220162163-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-05-26 — — US disclosed
US-20220162163-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-05-26 — — US disclosed
CN-114423753-A Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2022-04-29 — — CN disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 — — EP disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 — — EP disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 — — US disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 — — US disclosed
EP-3390384-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS Astex Therapeutics Limited (GB) 2018-10-24 — — EP disclosed
WO-2017103851-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2017-06-22 — — WO disclosed
WO-2017103851-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2017-06-22 — — WO disclosed
US-20170037004-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2017-02-09 — — US disclosed
US-20170037004-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2017-02-09 — — US disclosed
US-20170037004-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2017-02-09 — — US disclosed
WO-2017011371-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS, INC (US) 2017-01-19 — — WO disclosed
US-20170008904-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2017-01-12 — — US disclosed
US-8912180-B2 Heterocyclic compound ASTELLAS PHARMA INC. (JP) 2014-12-16 — — US disclosed
US-8912180-B2 Heterocyclic compound ASTELLAS PHARMA INC. (JP) 2014-12-16 — — US disclosed
US-20130150364-A1 HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2013-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008904-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, XIAP, TP53 YTHDC1 4204/4885SLC6A2 4808/4885SLC6A4 4655/4885
US-20220162163-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE XIAP, BIRC3, BIRC2 YTHDC1 4097/4885SLC6A2 4185/4885SLC6A4 4076/4885
US-20130150364-A1 HETEROCYCLIC COMPOUND IL2, NFATC1, ICOS YTHDC1 3987/4885SLC6A2 4414/4885SLC6A4 4701/4885
US-20210238162-A1 CHEMICAL COMPOUNDS HPGDS, PTGS1, PTGIS YTHDC1 3834/4885SLC6A2 3652/4885SLC6A4 3079/4885
US-20230158024-A1 CD38 INHIBITORS CD38, NQO1, NDUFAB1 YTHDC1 2285/4885SLC6A2 974/4885SLC6A4 3684/4885
US-20170037004-A1 ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE XIAP, BIRC3, BIRC2 YTHDC1 4097/4885SLC6A2 4185/4885SLC6A4 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.